CHEK1 and acute myeloid leukemia: The recent study, which provided RNA sequencing data set on AraC-treated patient samples that we used in our analysis, suggests that the activity of ATR/Chk1 pathway is necessary to induce reversible senescence like-phenotype in AML cells treated with high doses of AraC just before reaching a critical toxic dose that killed these cells21.